Springworks Therapeutics, INC
Market Movers (8-K)
SpringWorks Therapeutics, Inc. has completed its acquisition by Merck KGaA for $47.00 per share in cash, leading to its delisting from The Nasdaq Stock Market.
SpringWorks Therapeutics, Inc. announced that its stockholders overwhelmingly approved the proposed merger agreement with Merck KGaA, Darmstadt, Germany, at a special meeting held on June 26, 2025.
SpringWorks Therapeutics, Inc. announced the satisfaction of critical antitrust conditions for its proposed merger with Merck KGaA, including the expiration of the HSR Act waiting period and Bundeskartellamt approval, moving closer to a second-half 2025 consummation.
SpringWorks Therapeutics held its annual meeting on May 14, 2025, electing directors, ratifying the appointment of Ernst & Young LLP as its independent auditor, and approving executive compensation.
8-K: Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion, Expanding Rare Tumor Portfolio
Merck KGaA, Darmstadt, Germany will acquire SpringWorks Therapeutics for $47 per share in cash, valuing the company at approximately $3.9 billion, to bolster its healthcare business and expand its presence in the rare tumor market.
Capital raise
SpringWorks Therapeutics announces positive Q4 and full year 2024 financial results, driven by OGSIVEO sales and the FDA approval of GOMEKLI.
Quarterly Earnings (10-Q)
SpringWorks Therapeutics reports a significant increase in product revenue for Q1 2025, driven by sales of OGSIVEO and GOMEKLI, while also announcing a pending acquisition by Merck KGaA.
Better than expected
SpringWorks Therapeutics reported $49.3 million in product revenue for the third quarter of 2024, driven by sales of OGSIVEO, and is progressing its pipeline with regulatory submissions for mirdametinib.
Better than expected
SpringWorks Therapeutics reported a net product revenue of $40.2 million for the second quarter of 2024, driven by the commercial launch of OGSIVEO.
Better than expected
SpringWorks Therapeutics reported $21.0 million in net product revenue from OGSIVEO sales in the first quarter of 2024, marking its first commercial revenue.
Worse than expected
Annual Reports (10-K)
SpringWorks Therapeutics highlights its commercial progress with OGSIVEO and GOMEKLI, along with ongoing clinical development and strategic partnerships in its 2024 10-K filing.
SpringWorks Therapeutics details its authorized capital stock, common and preferred stock rights, and anti-takeover provisions in its recent 10-K filing.
Capital raise
Insider Trading (Form 4)
Form 4: SpringWorks Therapeutics Director Disposes of Shares and Options Following Merger with Merck KGaA
A director of SpringWorks Therapeutics, Inc. has reported the disposition of common stock and stock options following the company's acquisition by Merck KGaA for $47.00 per share in cash.
Form 4: SpringWorks Therapeutics COO Disposes of Equity Holdings Following Merck KGaA Merger Completion
SpringWorks Therapeutics' Chief Operating Officer, Edris Badreddin, disposed of all beneficial ownership in the company's securities, including common stock, restricted stock units, performance share units, and stock options, as a result of the company's acquisition by Merck KGaA for $47.00 per share.
Form 4: SpringWorks Therapeutics Director Disposes of Shares and Options Following Merger with Merck KGaA
Daniel Lynch, a Director at SpringWorks Therapeutics, Inc., has reported the disposition of all his common stock, restricted stock units, and stock options as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025.
SpringWorks Therapeutics, Inc. has completed its merger with Merck KGaA, Darmstadt, Germany, resulting in the conversion of all outstanding shares, restricted stock units, and stock options into cash or cash-based awards.
A director of SpringWorks Therapeutics, Inc. reported the complete disposition of common stock, restricted stock units, and stock options as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, at a cash consideration of $47.00 per share.
SpringWorks Therapeutics, Inc. Director Alan Fuhrman has disposed of all his common stock and stock options, totaling 24,727 shares and 78,755 options, respectively, as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, at a cash consideration of $47.00 per share.
Proxy Statements (Def-14A)
SpringWorks Therapeutics, Inc. announced that the Bundeskartellamt approval and the HSR Act waiting period expiration, two critical conditions for its merger with Merck KGaA, have been satisfied, moving the acquisition closer to its expected consummation in the second half of 2025.
DEFM14A: SpringWorks Therapeutics to be Acquired by Merck KGaA for $47.00 Per Share in All-Cash Transaction
SpringWorks Therapeutics, Inc. has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $47.00 per share in cash, representing a 26% premium to its unaffected 20-day volume-weighted average price.
Delay expected
Merck KGaA, Darmstadt, Germany, will acquire SpringWorks Therapeutics for $47.00 per share in cash, pending shareholder and regulatory approval, expected to close in the second half of 2025.
DEFA14A: Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion, Expanding Rare Tumor Portfolio
Merck KGaA, Darmstadt, Germany, will acquire SpringWorks Therapeutics for $47 per share in cash, a deal valued at approximately $3.9 billion, to bolster its healthcare business and expand its presence in the rare tumor treatment market.
Capital raise
SpringWorks Therapeutics will hold its annual stockholder meeting virtually on May 14, 2025, to vote on director elections, auditor ratification, and executive compensation.
SpringWorks Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on May 14, 2025, to vote on director elections, auditor ratification, executive compensation, and other business.
Schedule 13G - Passive Investments
The Goldman Sachs Group and its subsidiary, Goldman Sachs & Co. LLC, reported a 0.0% beneficial ownership stake in Springworks Therapeutics, Inc. as of September 30, 2025.
The Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have disclosed a 5.6% beneficial ownership stake in SpringWorks Therapeutics, Inc.
Hudson Bay Capital Management LP and Sander Gerber have disclosed a 5.22% beneficial ownership stake in SpringWorks Therapeutics, Inc., including shares from call options.
Glazer Capital, LLC and Paul J. Glazer have reported that their beneficial ownership in SpringWorks Therapeutics, Inc. has fallen to 0.00%, triggering a Schedule 13G filing.
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 1.7% beneficial ownership stake in SpringWorks Therapeutics Inc. as of April 30, 2025.
Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd. and David Kroin, has reported a passive beneficial ownership of 4.65% in Springworks Therapeutics, Inc. as of December 31, 2024.